NZ504420A - Combination of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia - Google Patents

Combination of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia

Info

Publication number
NZ504420A
NZ504420A NZ504420A NZ50442098A NZ504420A NZ 504420 A NZ504420 A NZ 504420A NZ 504420 A NZ504420 A NZ 504420A NZ 50442098 A NZ50442098 A NZ 50442098A NZ 504420 A NZ504420 A NZ 504420A
Authority
NZ
New Zealand
Prior art keywords
tetrahydropyridine
ethyl
trifluoromethylphenyl
biphenylyl
alkyl
Prior art date
Application number
NZ504420A
Other languages
English (en)
Inventor
Jean-Pierre Maffrand
Philippe Soubrie
Jean-Paul Terranova
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9714322A external-priority patent/FR2771007B1/fr
Priority claimed from FR9714324A external-priority patent/FR2771006B1/fr
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of NZ504420A publication Critical patent/NZ504420A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ504420A 1997-11-14 1998-11-09 Combination of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia NZ504420A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9714322A FR2771007B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer
FR9714324A FR2771006B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer
PCT/FR1998/002384 WO1999025363A1 (fr) 1997-11-14 1998-11-09 Association de principes actifs, notamment de tetrahydropyridines et d'agents inhibiteurs de l'acetylcholinesterase, pour le traitement de la demence senile du type alzheimer

Publications (1)

Publication Number Publication Date
NZ504420A true NZ504420A (en) 2003-08-29

Family

ID=26233932

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ504420A NZ504420A (en) 1997-11-14 1998-11-09 Combination of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia

Country Status (27)

Country Link
EP (1) EP1030671A1 (ko)
JP (1) JP2001523642A (ko)
KR (1) KR100599350B1 (ko)
CN (1) CN1243540C (ko)
AU (1) AU743228B2 (ko)
BG (1) BG64819B1 (ko)
BR (1) BR9814035A (ko)
CA (1) CA2309966A1 (ko)
CO (1) CO4980891A1 (ko)
DZ (1) DZ2649A1 (ko)
EA (1) EA003255B1 (ko)
EE (1) EE04235B1 (ko)
HU (1) HUP0100098A3 (ko)
ID (1) ID24933A (ko)
IL (2) IL136122A0 (ko)
IS (1) IS5482A (ko)
MY (1) MY120461A (ko)
NO (1) NO20002450L (ko)
NZ (1) NZ504420A (ko)
OA (1) OA11464A (ko)
PL (1) PL194597B1 (ko)
SA (1) SA98190747B1 (ko)
SK (1) SK286040B6 (ko)
TR (1) TR200001262T2 (ko)
TW (1) TW585766B (ko)
UY (1) UY25247A1 (ko)
WO (1) WO1999025363A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2389937T1 (sl) 2002-06-14 2018-10-30 Toyama Chemical Co., Ltd, Farmacevtska sestava za izboljšanje možganske funkcije
ES2327914T3 (es) * 2002-08-07 2009-11-05 Novartis Ag Metodo para pronosticar la sensibilidad al tratamiento con ravastigmina basado en el genotipo apoe de pacintes con demencia.
CN1520818A (zh) * 2003-02-09 2004-08-18 山东绿叶天然药物研究开发有限公司 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
US9796672B2 (en) 2014-01-31 2017-10-24 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
MX2019013524A (es) * 2017-05-15 2020-02-10 Cognition Therapeutics Inc Composiciones para tratar enfermedades neurodegenerativas.
KR102224918B1 (ko) 2018-03-20 2021-03-09 (주)인벤티지랩 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법
WO2019182319A1 (ko) * 2018-03-20 2019-09-26 (주)인벤티지랩 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
CN109265391B (zh) * 2018-11-13 2021-11-19 枣庄学院 联苯多取代1,2,5,6-四氢吡啶化合物及其合成方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5453428A (en) * 1991-02-14 1995-09-26 The Mount Sinai School Of Medicine Of The City Of New York Method and composition for the treatment of apathy-amotivation syndrome
PL185124B1 (pl) * 1995-03-06 2003-02-28 Interneuron Pharmaceuticals Zastosowanie cytykoliny oraz jej kompozycja do wytwarzania leku przeznaczonego do ochrony tkanki mózgowej
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US8507527B2 (en) 2004-12-27 2013-08-13 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug

Also Published As

Publication number Publication date
DZ2649A1 (fr) 2004-12-28
IL136122A (en) 2006-07-05
EE04235B1 (et) 2004-02-16
CA2309966A1 (en) 1999-05-27
OA11464A (en) 2003-11-18
AU1160999A (en) 1999-06-07
BR9814035A (pt) 2000-09-26
TR200001262T2 (tr) 2001-01-22
SK286040B6 (sk) 2008-01-07
EP1030671A1 (fr) 2000-08-30
WO1999025363A1 (fr) 1999-05-27
EA200000412A1 (ru) 2000-12-25
PL194597B1 (pl) 2007-06-29
CN1285742A (zh) 2001-02-28
PL340500A1 (en) 2001-02-12
CN1243540C (zh) 2006-03-01
ID24933A (id) 2000-08-31
AU743228B2 (en) 2002-01-24
BG104428A (en) 2001-08-31
BG64819B1 (bg) 2006-05-31
KR20010032099A (ko) 2001-04-16
CO4980891A1 (es) 2000-11-27
NO20002450D0 (no) 2000-05-11
SK7112000A3 (en) 2000-10-09
EE200000290A (et) 2001-06-15
TW585766B (en) 2004-05-01
IS5482A (is) 2000-05-09
HUP0100098A3 (en) 2001-12-28
SA98190747B1 (ar) 2006-11-04
UY25247A1 (es) 2001-05-31
EA003255B1 (ru) 2003-02-27
JP2001523642A (ja) 2001-11-27
HUP0100098A2 (hu) 2001-07-30
NO20002450L (no) 2000-07-14
KR100599350B1 (ko) 2006-07-12
MY120461A (en) 2005-10-31
IL136122A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
EP0216555B1 (en) Use of dioxopiperidine derivatives in the treatment of anxiety, for the reduction of chronic abnormally high brain levels of serotonin or 5-hydroxy-indoleacetic acid, and in the treatment of bacterial or viral infections
Settle Bupropion sustained release: side effect profile
AU753077B2 (en) Combination of a GABA-A alpha 5 inverse agonist and an acetylcholinesterase inhibitor
AU2004283425B2 (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
US20050148614A1 (en) Combination of active ingredients for the treatment of senile dementia of the Alzheimer type
MX2012004528A (es) Terapia con pirfenidona e inductores del citocromo p450.
NZ504420A (en) Combination of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia
JP3468526B2 (ja) 筋萎縮性側索硬化症治療薬調製のための１−（２−ナフタ−２−イルエチル）−４−（３−トリフルオロメチルフェニル）−１，２，３，６−テトラヒドロピリジンの使用
ZA200508067B (en) Combination comprising paroxetine and 2-(s)-(4-fluoro-2-methyl-phenyl) -piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide for treatment of depression and/or anxiety
MXPA00004600A (en) Combination of active principles, in particular of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia
CZ20001734A3 (cs) Farmaceutická kompozice a její použití
WO1998034615A1 (en) Pharmaceutical composition for treatment of synaptic dysfunction comprising an oxime
CA2188227C (en) Combination antiemetic therapy using nk-1 receptor antagonists
SI21062A2 (sl) Farmacevtski sestavki, ki obsegajo amlodipin maleat
FR2771007A1 (fr) Association de principes actifs pour le traitement de la demence senile du type alzheimer

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)